Stocks · News reference
This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Top analysts change outlook on ALNY, AGMB, BMRN, BEKE, and IONS with ratings and price targets. Check out opinions and coverage on Benzinga.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
This Agomab Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Analysts change outlook on top names. See all rating changes, including upgrades/downgrades/initiations. Coverage initiated on various stocks.
Piper Sandler Initiates Coverage On AgomAb Therapeutics with Overweight Rating, Announces Price Target of $60
Piper Sandler analyst Yasmeen Rahimi initiates coverage on AgomAb Therapeutics (NASDAQ:AGMB) with a Overweight rating and announces Price Target of $60.
HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $455 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and maintains $455 price target.
Reported Earlier, Alnylam Highlights AMVUTTRA Results And New RNAi Approach For High Blood Pressure
Alnylam Pharmaceuticals To Present New Clinical And Real-World Data Across Its Transthyretin-Mediated Amyloidosis And Hypertension Programs At ESC Congress 2026